• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ELAN

    Elanco Animal Health Incorporated

    Subscribe to $ELAN
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

    IPO Year: 2018

    Exchange: NYSE

    Website: elanco.com

    Recent Analyst Ratings for Elanco Animal Health Incorporated

    DatePrice TargetRatingAnalyst
    12/9/2024$18.00Buy
    UBS
    12/2/2024$14.00Market Perform
    Leerink Partners
    9/19/2024$17.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/5/2024$13.00 → $20.00Hold → Buy
    Stifel
    12/19/2023$17.00Buy
    Jefferies
    12/15/2023$16.00Equal-Weight → Overweight
    Morgan Stanley
    12/7/2023$18.00Outperform
    Exane BNP Paribas
    4/20/2023$14.00Equal Weight → Overweight
    Barclays
    8/18/2022$37.00 → $22.00Overweight → Equal-Weight
    Morgan Stanley
    8/16/2022$28.00 → $24.00Overweight → Neutral
    JP Morgan
    See more ratings

    Elanco Animal Health Incorporated Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elanco Animal Health Reports First Quarter 2025 Results

      Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

      5/7/25 6:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

      GREENFIELD, Ind., May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. Monetization of this non-core asset will be used to accelerate debt reduction, positioning Elanco to achieve an expected net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end of 2025. Elanco will repay portions of its outstanding term loans on a pro-rata basis, which is expected to reduce inte

      5/5/25 6:27:00 AM ET
      $ELAN
      $TARS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day

      National Parvo Awareness Day raises awareness of canine parvovirus (parvo), the often-fatal puppy disease.Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) is the first-and-only USDA conditionally approved treatment for parvo.Puppies treated with CPMA had a 93% survival rate and returned home an average of 1.87 days sooner.1,2Elanco's ParvoTrack, the first-ever national online parvo tracking tool, allows pet owners and veterinarians to self-report outbreaks in real time, further highlighting the need for CPMA across the country and reinforcing Elanco's commitment to increasing the availability of CPMA.Texas, Arizona, Georgia, Florida, Illinois, Indiana and New York have some of the highe

      4/22/25 8:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement

      GREENFIELD, Ind., April 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2025 financial results on Wednesday, May 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/defau

      4/10/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets

      GREENFIELD, Ind., March 17, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced changes to its Board of Directors that will reduce the Board size to 11 directors by the 2025 Annual Meeting of Shareholders: John P. (JP) Bilbrey, Kathy Turner and Craig Wallace have each informed the Board they will not stand for re-election at the conclusion of their terms at the 2025 Annual Meeting of Shareholders.William F. (Bill) Doyle has resigned from the Board, effective immediately, in connection with entering into a research agreement with Elanco through hi

      3/17/25 4:17:00 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Enters Agreement with Medgene to Commercialize Highly Pathogenic Avian Influenza Vaccine in Dairy Cattle

      GREENFIELD, Ind., Feb. 25, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced it has entered into an agreement with South Dakota-based Medgene to leverage the company's innovative vaccine platform technology. The agreement includes commercialization of a highly pathogenic avian influenza (HPAI) vaccine for use in dairy cattle. Medgene reports the vaccine has met all requirements of the U.S. Department of Agriculture's (USDA) platform technology guidelines and is in the final stages of review for conditional license approval. While the poultry in

      2/25/25 7:05:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco to Participate in Upcoming Investor Conferences

      GREENFIELD, Ind., Feb. 21, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that the Company will participate in the following investor conferences. On Thursday, February 27, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Bank of America 2025 Animal Health Summit at 12:30 p.m. ET. On Monday, March 3, Jeff Simmons, president and CEO, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference at 3:10 p.m. ET. On Tuesday, March 11, Todd Young, executive vice president and CFO,

      2/21/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Launches Pet Protect™ From the Makers of Advantage®: Veterinarian-Formulated Supplements for Complete Pet Wellness

      Pet Protect offers a comprehensive line of veterinarian-formulated, science-backed supplements.The U.S. pet supplement market is growing as pet parents increasingly desire proactive wellness options.Pet Protect features products for both dogs and cats, including joint health, multivitamins, Omega-3, fast-acting calming, allergy and immune support, digestive function support and more.The launch of Pet Protect from the Makers of Advantage strengthens Elanco's position as a leader in the pet health market and offers a science-backed brand to the supplements category. The Advantage brand is a trusted leader in pet health for 25 years.GREENFIELD, Ind., Feb. 20, 2025 /PRNewswire/ -- Elanco Animal

      2/20/25 8:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Reinforces Commitment to Veterinary and Pet Owner Education

      GREENFIELD, Ind., Feb. 13, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated issued the following statement regarding its commitment to clear veterinary and pet owner education following a promotional practices warning letter from U.S. Food and Drug Administration (FDA). At Elanco, we are dedicated to helping veterinarians and pet owners help pets live longer, healthier, more active lives. Delivering new innovation to the marketplace and ensuring we clearly communicate with veterinarians and pet owners about how to safely and effectively use these products is a key part o

      2/13/25 4:29:00 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2024 Financial Results Announcement

      GREENFIELD, Ind., Feb. 4, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-pr

      2/4/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Elanco Animal Health Incorporated Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      7/8/24 4:32:39 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      2/13/24 2:08:55 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      2/12/24 4:01:30 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Elanco Animal Health Incorporated

      SC 13G - Elanco Animal Health Inc (0001739104) (Subject)

      1/29/24 5:25:49 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      11/8/23 4:01:03 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      9/11/23 1:33:44 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      6/8/23 1:25:21 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      2/14/23 1:44:59 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      2/14/23 12:38:10 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      2/9/23 4:02:24 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Elanco Animal Health Incorporated Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Modi Rajeev A.

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      5/6/25 4:04:57 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      5/6/25 4:04:28 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      4/22/25 5:21:32 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Modi Rajeev A.

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      4/22/25 5:21:11 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      4/8/25 5:59:51 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Modi Rajeev A.

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      4/8/25 5:58:45 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Bettington Timothy J covered exercise/tax liability with 23,558 shares, decreasing direct ownership by 18% to 110,262 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      4/7/25 4:27:46 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Anand Kapila K

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      4/2/25 5:41:44 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Modi Rajeev A.

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/25/25 7:12:18 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/25/25 7:11:31 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Elanco Animal Health Incorporated SEC Filings

    See more
    • SEC Form 10-Q filed by Elanco Animal Health Incorporated

      10-Q - Elanco Animal Health Inc (0001739104) (Filer)

      5/7/25 9:05:18 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Elanco Animal Health Inc (0001739104) (Filer)

      5/7/25 6:30:46 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Elanco Animal Health Incorporated

      DEFA14A - Elanco Animal Health Inc (0001739104) (Filer)

      3/27/25 12:30:40 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Elanco Animal Health Incorporated

      DEF 14A - Elanco Animal Health Inc (0001739104) (Filer)

      3/27/25 12:21:58 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Elanco Animal Health Inc (0001739104) (Filer)

      3/17/25 4:20:16 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elanco Animal Health Incorporated

      SCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      3/7/25 10:01:30 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Elanco Animal Health Incorporated

      10-K - Elanco Animal Health Inc (0001739104) (Filer)

      2/25/25 9:12:37 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Elanco Animal Health Inc (0001739104) (Filer)

      2/25/25 7:05:31 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Elanco Animal Health Incorporated

      SCHEDULE 13G - Elanco Animal Health Inc (0001739104) (Subject)

      2/12/25 9:08:29 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Elanco Animal Health Inc (0001739104) (Filer)

      1/13/25 8:31:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Elanco Animal Health Incorporated Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/11/25 5:13:30 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/7/25 4:21:21 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      8/26/24 5:05:35 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $1,300,610 worth of shares (100,000 units at $13.01) (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      8/13/24 9:04:50 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Doyle William F bought $254,700 worth of shares (15,000 units at $16.98), increasing direct ownership by 24% to 76,330 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      5/23/24 4:33:35 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Doyle William F bought $244,500 worth of shares (15,000 units at $16.30), increasing direct ownership by 32% to 61,330 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/12/24 4:32:22 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrington Michael J bought $50,494 worth of shares (3,100 units at $16.29), increasing direct ownership by 4% to 77,594 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/12/24 4:30:07 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoover R David bought $322,808 worth of shares (20,000 units at $16.14) (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/8/24 5:09:02 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Elanco Animal Health Incorporated Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Elanco Animal Health with a new price target

      UBS initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $18.00

      12/9/24 7:40:18 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Elanco Animal Health with a new price target

      Leerink Partners initiated coverage of Elanco Animal Health with a rating of Market Perform and set a new price target of $14.00

      12/2/24 6:55:44 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Elanco Animal Health from Overweight to Equal-Weight and set a new price target of $15.00 from $17.00 previously

      9/19/24 7:41:39 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health upgraded by Stifel with a new price target

      Stifel upgraded Elanco Animal Health from Hold to Buy and set a new price target of $20.00 from $13.00 previously

      1/5/24 7:41:08 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Elanco Animal Health with a new price target

      Jefferies initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $17.00

      12/19/23 7:45:17 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Elanco Animal Health from Equal-Weight to Overweight and set a new price target of $16.00

      12/15/23 8:08:21 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exane BNP Paribas initiated coverage on Elanco Animal Health with a new price target

      Exane BNP Paribas initiated coverage of Elanco Animal Health with a rating of Outperform and set a new price target of $18.00

      12/7/23 6:17:43 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health upgraded by Barclays with a new price target

      Barclays upgraded Elanco Animal Health from Equal Weight to Overweight and set a new price target of $14.00

      4/20/23 7:20:02 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Elanco Animal Health from Overweight to Equal-Weight and set a new price target of $22.00 from $37.00 previously

      8/18/22 7:21:41 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health downgraded by JP Morgan with a new price target

      JP Morgan downgraded Elanco Animal Health from Overweight to Neutral and set a new price target of $24.00 from $28.00 previously

      8/16/22 7:50:32 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Elanco Animal Health Incorporated Financials

    Live finance-specific insights

    See more
    • Elanco Animal Health Reports First Quarter 2025 Results

      Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

      5/7/25 6:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement

      GREENFIELD, Ind., April 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2025 financial results on Wednesday, May 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/defau

      4/10/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2024 Financial Results Announcement

      GREENFIELD, Ind., Feb. 4, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-pr

      2/4/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Acquires Speke Contract Manufacturing Facility, Securing Key Supply Chain

      GREENFIELD, Ind., Nov. 15, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today acquired a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Speke Ltd., was under trading administration, a formal insolvency process in the United Kingdom. As previously shared on the Company's third quarter 2024 earnings call, the Speke facility plays a vital role for Elanco in producing a number of farm animal product lines, representing approximately $160 million to $180 million in annual farm animal revenue, primarily

      11/15/24 11:30:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for Third Quarter 2024 Financial Results Announcement

      GREENFIELD, Ind., Oct. 10, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2024 financial results on Thursday, November 7, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/de

      10/10/24 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Announces FDA Approval and Launch of Zenrelia™ (ilunocitinib tablets), Offering An Effective, Safe Solution in Canine Dermatology

      U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitisElanco enters the estimated $1.7 billion global canine dermatology market, highly accretive to existing portfolioIn a head-to-head study, Zenrelia was shown to be at least as effective as the market incumbent JAK inhibitor at the primary end point, with an additional endpoint at which Zenrelia got 77% of dogs to clinical remission of itch, compared to 53% of dogs treated with Apoquel® (oclacitinib tablet)1*Zenrelia launch begins in U.S. with Elanco now taking orders; product expected to ship in coming daysGREENFIELD, Ind., Sept. 19, 2024 /PRNewswire/ -- Elanco Anim

      9/19/24 3:08:00 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for Second Quarter 2024 Financial Results Announcement

      GREENFIELD, Ind., July 18, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2024 financial results on Thursday, August 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/def

      7/18/24 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health Reports First Quarter 2024 Results

      First Quarter 2024 Financial ResultsRevenue of $1,205 millionReported Net income of $32 million, Adjusted Net income of $167 millionAdjusted EBITDA of $294 million, or 24.4% of RevenueReported EPS of $0.06, Adjusted EPS of $0.34 Net leverage ratio of 6.1x Adjusted EBITDAYear over year growth rates are meaningfully impacted by a shift in customer purchasing related to the ERP Blackout in 2023, with an estimated $90 to $110 million of revenue shift from the second quarter of 2023 into the first quarter of 2023Updating full year 2024 financial guidance to reflect first quarter outperformance offset by expected unfavorable impact of foreign exchange rates:Revenue of $4,460 to $4,515 million, con

      5/8/24 6:28:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for First Quarter 2024 Financial Results Announcement

      GREENFIELD, Ind., April 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/defau

      4/17/24 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2023 Financial Results Announcement

      GREENFIELD, Ind., Feb. 8, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2023 financial results on Monday, February 26, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website on our events and presentations page. A repla

      2/8/24 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Elanco Animal Health Incorporated Leadership Updates

    Live Leadership Updates

    See more
    • Elanco Strengthens Board of Directors with Addition of Stacey Ma

      Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen

      11/12/24 8:33:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors

      New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner brings significant global experience in both the animal health and broader healthcare industries. She has held senior leadership positions at IDEXX Labora

      4/1/24 6:30:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Appoints Shiv O'Neill as General Counsel and Corporate Secretary

      GREENFIELD, Ind., March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE:ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts. "Shiv's ability to deliver strategic value to Elanco in the short term serving as our interim general counsel combined with her robust experience made it clear that she was the right person for this role," said Jeff Simmons,

      3/4/24 8:33:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Launches Multi-Year Mission to Save 1 Million Puppies from Canine Parvovirus

      Calling all Veterinarians and Pet Lovers - Take the "Defend Puppies. Defeat Parvo." Pledge Today to Save Puppies from Deadly Canine Parvovirus  GREENFIELD, Ind., Jan. 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today launched the first-of-its-kind, multi-year campaign to save 1 million puppies from unnecessary death from the highly contagious canine parvovirus (parvo). The Defend Puppies. Defeat Parvo. mission seeks to conquer a virus that, without timely and aggressive care, has a mortality rate as high as 91%1. An estimated 900 dogs are diagnosed with parvo daily2 in the U.S. – mostly unvaccinated puppies. Yet Elanco research revealed only 44% of dog owners know

      1/17/24 8:30:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kirk McDonald Appointed to Ziff Davis Board of Directors

      Ziff Davis, Inc. (NASDAQ:ZD), today announced the appointment of Kirk McDonald to its Board of Directors, effective November 15, 2023. McDonald is a highly accomplished executive with extensive experience and a career spanning more than three decades in media, technology, and advertising. "We are thrilled to welcome Kirk to our Board of Directors," said Ziff Davis Board Chair Sarah Fay. "As an industry veteran known for his business leadership, he will be an asset to Ziff Davis." McDonald serves as CEO of GroupM North America, a leading media investment agency. He announced that he will leave the role at year end. Prior to this, he was Chief Business Officer of Warner Media's Xandr when

      11/16/23 4:35:00 PM ET
      $ELAN
      $ZD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Telecommunications Equipment
      Telecommunications
    • Elanco Adds Animal Health Veteran to Executive Committee

      Tim Bettington joins Elanco as EVP Corporate Strategy and Market Development Elanco Animal Health (NYSE:ELAN) announced today the appointment of Tim Bettington as the company's executive vice president Corporate Strategy and Market Development. He will join Elanco's executive committee on March 20. As Elanco shifts from the separation and stand up of the independent company and the integration of the Bayer Animal Health acquisition to an increasing focus on delivering its next era of innovation and growth, Bettington's expertise complements the company's existing commercial leadership team. In his role, Bettington will be responsible for corporate strategy and market development, focused

      2/20/23 4:30:00 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors

      TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops po

      10/24/22 9:00:00 AM ET
      $ELAN
      $PRTS
      $TSPQ
      $KIN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Auto & Home Supply Stores
      Consumer Discretionary
    • US Foods Announces CEO Transition and Board Changes

      Pietro Satriano Steps Down as CEO and Will Not Stand for Re-election as Director at 2022 Annual Meeting of Shareholders Robert M. Dutkowsky to Serve as Executive Chair and Andrew Iacobucci to Serve as Interim CEO Board Has Commenced Search for Permanent CEO Appoints James J. Barber, Jr., Scott D. Ferguson and David A. Toy to Board Pursuant to Agreement with Sachem Head Reaffirms Fiscal Year 2022 Guidance US Foods Holding Corp. (NYSE:USFD) ("US Foods" or the "Company"), one of the largest foodservice distributors in the United States, today announced a transition of its Chief Executive Officer. The Company also announced changes to its Board of Directors in connection with a cooperation

      5/10/22 6:58:00 AM ET
      $ADSK
      $ELAN
      $EMN
      $KHC
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Announces the Addition of Rajeev (Bobby) Modi to Lead U.S. Pet Health

      Elanco Animal Health (NYSE:ELAN) announced today the appointment of Rajeev (Bobby) Modi as the company's executive vice president U.S. Pet Health and Global Digital Transformation. He will join the company on March 14 and will serve on the company's executive committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220222005316/en/Elanco welcomes Bobby Modi as executive vice president U.S. Pet Health and Global Digital Transformation. With a track record of building and growing consumer brands and a history within the pet industry, Bobby is positioned to lead and grow our business as we continue to transform our digital strategy

      2/22/22 4:35:00 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scout Bio Appoints Life Sciences Executive Aaron Schacht to Board of Directors

      Brings experience in managing global innovation portfolios and business development to Scout BioExecutive leadership experience across both animal and human health PHILADELPHIA, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Scout Bio, a biotechnology company developing therapeutic proteins and one-time AAV gene therapies for major chronic pet health conditions announced it had appointed Aaron Schacht to its Board of Directors. Mr. Schacht is a deeply experienced life sciences executive with management expertise across a wide range of functions and will work with Scout Bio to execute its strategic development as a veterinary biopharma pioneer. "Scout Bio's approach to the innovation and delivery of e

      2/18/22 5:30:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care